- **CEO Focus**: Operational excellence, leadership evaluation, and $200M EBITDA opportunity from 2023-2026 facilities. 
- **Financial Highlights**: Q4 2025 Revenue $821.5M, 2026 Outlook $3.37-3.45B. 
- **Growth Drivers**: 630 new beds, 1-2% core growth, 2-3% pricing. 
- **Challenges**: New York Medicaid ($25-30M EBITDA impact), California staffing costs. 
- **Free Cash Flow**: Expected in 2026 with reduced CapEx. 
- **Key Risks**: Regulatory changes, start-up losses ($47-53M in 2026).

**【CEO Summary Section】**
- Debra Osteen emphasized stability, execution, and communication as her priorities. She is evaluating leadership depth, focusing on operational fundamentals, and addressing delays in new facility ramp-ups. 
- The company added 1,089 beds in 2025, with 400-600 more expected in 2026, primarily through joint ventures. 
- A $200 million EBITDA opportunity is projected from 2023-2026 facilities, achievable within 5 years. 
- Quality dashboards track 50 metrics, improving transparency and patient outcomes. 
- New York Medicaid changes may reduce EBITDA by $25-30 million annually, prompting consolidation of Pennsylvania facilities. 

**【CFO Financial Commentary】**
- Q4 2025: Revenue $821.5M (+6.1% YoY), Adjusted EBITDA $99.8M. Start-up losses $12.8M, up from $11.2M YoY. 
- Full year 2025: Revenue $3.31B (+5% YoY), Adjusted EBITDA $608.9M. 
- 2026 Outlook: Revenue $3.37-3.45B, Adjusted EBITDA $575-610M. 
- Same-facility volume growth 0-1%, driven by 630 new beds. Pricing +2-3%, offset by $34M loss of Tennessee supplemental payments. 
- Start-up losses $47-53M, declining post-2026. Free cash flow expected with CapEx $255-280M. 
- PLGL expenses $100-110M, down 69% QoQ in Q4. 

**【Q&A Highlights】**
- **Value Creation Review**: Ongoing, focusing on short-term execution and long-term value. 
- **Growth Algorithm**: Demand remains strong; 1-2% core growth + 1-2% from ramping facilities. 
- **California Staffing**: $4M EBITDA impact from new regulations, expected in Q2. 
- **Bed Closures**: 5 facilities closed in 2025; no closures planned in 2026. 
- **Diluted Leverage**: 4x, improving with EBITDA growth. 
- **New York Impact**: Consolidating Pennsylvania facilities, seeking new payer mix. 
- **Q1 2026 Guidance**: EBITDA $130-137M, includes $11M out-of-period payments and $3.7M weather impact.

Acadia Healthcare Company, Inc.(ACHC)-20260225-2025 Q4 Earnings call transcript

- **Q3 Results**: Revenue growth (+4.4%) offset by EBITDA decline (-11.3%) due to Medicaid volume softness and cost pressures.
- **Strategic Shifts**: $300M+ CapEx reduction for 2026, 5 facility closures, and 500-700 new beds planned for next year.
- **Quality Focus**: 6 consecutive quarters of improved retention, 50+ clinical KPIs tracked, and JV facility showing 47% reduction in depressive symptoms.
- **2025 Outlook**: Adjusted EBITDA revised to $650-660M, with 2026 targeting positive free cash flow.
- **Risks**: Medicaid rate pressure, PLGL expenses, and delayed CMS payments weighing on margins.

**【Management Opening Remarks】**
- Brian Farley provided an overview of the Q3 2025 earnings release, emphasizing forward-looking statements and the importance of GAAP/non-GAAP reconciliations.
- Highlighted Todd Young's recent appointment as CFO and his experience in healthcare finance.

**【CEO Summary Section】**
- **Q3 2025 Results**: Revenue of $851.6 million (+4.4% YoY), Adjusted EBITDA of $173 million (-11.3% YoY) due to Medicaid volume softness and cost pressures.
- **Strategic Adjustments**: Paused $300M+ in CapEx for 2026, focusing on high-return markets; closed 5 underperforming facilities to optimize portfolio.
- **Growth Initiatives**: 500-700 new beds expected in 2026, including JV partnerships with Tufts Medicine and Orlando Health.
- **Quality Investments**: 6 consecutive quarters of improved employee retention; new quality dashboard tracks 50+ KPIs, driving clinical outcomes (e.g., 47% reduction in depressive symptoms at a JV facility).

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP net income of $42.3 million, Non-GAAP EPS of $0.85 (down 22% YoY). Adjusted EBITDA of $173 million missed internal expectations by $5 million due to bad debt and PLGL expenses.
- **Balance Sheet**: $118.7M cash, $790M available on $1B revolver; net leverage ratio of 3.4x.
- **2025 Outlook**: Revised Adjusted EBITDA guidance to $650-660M (prev. $675-700M), driven by Medicaid rate pressure and volume declines.
- **2026 Outlook**: Free cash flow expected for the full year, with startup losses declining 20-30% YoY.

**【Q&A Key Highlights】**
- **Payer Challenges**: Medicaid managed care plans increasing utilization reviews, leading to shorter lengths of stay and higher denials (e.g., 3%+ incremental bad debt expense).
- **Cost Controls**: Legal expenses down 28% QoQ to $39M; expects further reductions in 2026.
- **CapEx Discipline**: 2026 CapEx guidance of $300-400M (prev. $610-630M), with 150-250 new beds in 2027.
- **Supplemental Payments**: Up to $22M potential EBITDA boost from CMS programs, though timing uncertain due to government shutdown.
- **Free Cash Flow**: 2026 target of positive full-year FCF, driven by reduced CapEx and ramping new beds.


Acadia Healthcare Company, Inc. (ACHC) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue up 9.2% YoY to $869.2 million, EBITDA +7.5% to $201.8 million.
- **Medicaid Challenges**: Medicaid volumes down 1.2% YoY, offset by +9% commercial and +8% Medicare.
- **Expansion Costs**: Start-up losses up $10 million YTD due to faster bed openings.
- **Free Cash Flow**: Potential 2026 acceleration via $100 million CapEx pause.
- **Risk Management**: $20 million EBITDA drag from underperforming facilities, one with media-related issues.
- **Leadership Change**: Heather Dixon departing; Tim Sides to lead interim CFO.

**【CEO Summary Section】**
- Q2 2025 revenue: $869.2 million (+9.2% YoY), adjusted EBITDA: $201.8 million (+7.5% YoY).
- Medicaid supplementals: $230 million expected in 2025, half at risk of 2028 reductions.
- Capacity expansion: 479 beds added YTD (101 in Q2), 11 new CTCs.
- Volume: Same-facility patient days +1.8% YoY, Medicaid down 1.2% YoY.
- Quality: Technology investments for patient safety and outcomes.
- Leadership: Heather Dixon stepping down; Tim Sides interim CFO.

**【CFO Financial Commentary】**
- Q2 EBITDA margin: 23.2%, Tennessee program contributed $51.8 million.
- Updated 2025 guidance: EBITDA $675-700 million, volume +2-3%, beds 950-1000.
- Liquidity: $131.4 million cash, $828 million credit facility available.
- Start-up costs: $14.2 million Q2, total YTD $28.8 million.

**【Q&A Key Highlights】**
- Medicaid decline: Managed care cost pressures reduced acute care admissions.
- CapEx pause: $100 million to accelerate free cash flow.
- Wage trends: Labor costs 3.5% YoY (down from 7.8%).
- Legal costs: $54 million Q2 on government investigations.

Acadia Healthcare Company, Inc. (ACHC) Q2 2025 Earnings Call Transcript

- **Q1 Financial Resilience**: Revenue and EBITDA in-line with guidance, despite 110bps leap year headwind.
- **Growth Ambition**: 801,000 new beds in 2025, targeting 600-800 beds/year from 2026.
- **Quality Differentiation**: 26,000+ employees supported by premium pay declines and data-driven care.
- **Policy Risk Management**: $20M EBITDA impact from underperforming facilities, with 2025 no material improvement.
- **Liquidity Strength**: $900M credit facility and $91.2M cash to fund expansion.

**【CEO Summary Section】**
- Q1 2025 revenue of $770.5M and adjusted EBITDA of $134.2M aligned with guidance, driven by 2.2% same-facility patient day growth.
- Added 378 new beds (288 from 2 new facilities) and 7 new CTCs, with 801,000 total beds expected in 2025.
- Emphasized quality initiatives, including 24/7 patient monitoring and data-driven care, to enhance recruitment and retention.
- Policy focus on supplemental payments, with Tennessee program approval expected to support Medicaid funding.

**【CFO Financial Commentary】**
- GAAP revenue up slightly YoY, with same-facility revenue per patient day flat due to supplemental payment timing.
- Adjusted EBITDA margin of 17.4%, impacted by $5M EBITDA headwind from facility closures.
- Full-year guidance reaffirmed: $3.0B-$3.1B revenue, $530M-$550M EBITDA, $1.80-$1.90 EPS.
- 2025 startup losses expected at $50M-$55M, with $15M in Q2.
- Cash of $91.2M and $900M available under credit facility, supporting strategic investments.

**【Q&A Key Highlights】**
- **EBITDA Progression**: Q1 startup costs highest, with Tennessee DPP approval key to Q2+ EBITDA growth.
- **Bed Ramp Assumptions**: 5-year ramp for new facilities, with 600-800 beds/year from 2026.
- **CTC Performance**: Sequential revenue flat despite 3% patient growth, due to rate timing and facility closures.
- **Underperforming Facilities**: $20M EBITDA headwind in 2025, with Q4 2025 comp relief.
- **Legal Costs**: Ongoing DOJ/SEC investigations, with Q1 costs reflecting active case management.

Acadia Healthcare (ACHC)-13 May 25-2025 Q1 Earnings call transcript

- **Q4 2024 Results**: $774M revenue (+4.2% YoY), $153.1M Adjusted EBITDA. Full-year 2024: $3.1B revenue (+7.7%).
- **2025 Guidance**: Revenue $3.3-3.4B, EBITDA $675-725M, EPS $2.50-2.80. CapEx $630-690M.
- **Growth Strategy**: 800-1,000 new beds in 2025, targeting 2026 EBITDA growth of 8-10%.
- **Key Risks**: $20M EBITDA headwind from underperforming facilities, +$10M in liability costs.
- **Free Cash Flow**: Expected positive by end of 2026 with declining CapEx.

**【CEO Summary Section】**
- Q4 2024 revenue reached $774 million, up 4.2% YoY, with full-year revenue of $3.1 billion (+7.7%).
- Same-facility patient days grew 3.2% in Q4, stable at 3-4% monthly. Excluding underperforming facilities, growth would have been >5%.
- 2024 bed construction: 1,300 new beds (776 operational), including 577 opened in Q4. 2025 target: 800-1,000 new beds.
- Emphasized patient safety tech investments: EMRs, monitoring devices, quality dashboards.
- Joint ventures with Intermountain Health and Henry Ford Health expanded capacity.

**【CFO Financial Commentary】**
- Q4 2024 Adjusted EBITDA: $153.1 million (19.8% margin). Full-year guidance 2025: $675-725 million.
- Start-up losses Q4: $11.2 million (+$6M YoY). 2025 total start-up costs: $50-55 million.
- 2025 revenue: $3.3-3.4 billion. EPS: $2.50-2.80. CapEx: $630-690 million.
- EBITDA headwind from underperforming facilities: $20 million YoY.
- 2026 outlook: EBITDA growth 8-10%, free cash flow positive.

**【Q&A Key Highlights】**
- **Capital Allocation**: $300M share buyback authorized. 2026+ free cash flow expected.
- **Growth Balance**: Moderate bed growth (600-800/yr) to balance EBITDA and FCF.
- **Supplemental Payments**: 2025 net impact flat to +$15M, but Q1 timing drag of -$10-15M.
- **Liability Costs**: +$10M YoY in professional liability expenses.
- **Underperforming Facilities**: 2025 EBITDA drag of $20M, no upside assumed.
- **Long-Term Outlook**: 7-9% revenue growth, 8-10% EBITDA growth by 2026.

Actual										0.42	0.54	0.68	1.13	0.47	0.71	0.72	0.81	0.67	0.84	0.8	0.7	0.75	0.92	0.91	0.85	0.84	0.91	0.91	0.64	0.4	0.83	0.72	0.07
Forecast										0.3802	0.3871	0.5374	0.6355	0.4449	0.6287	0.7242	0.6831	0.6355	0.778	0.7861	0.7494	0.7096	0.8576	0.8919	0.7926	0.7969	0.8763	0.8994	0.7146	0.3569	0.6948	0.6597	0.0089
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+10.47%	+39.50%	+26.54%	+77.81%	+5.64%	+12.93%	-0.58%	+18.58%	+5.43%	+7.97%	+1.77%	-6.59%	+5.69%	+7.28%	+2.03%	+7.24%	+5.41%	+3.85%	+1.18%	-10.44%	+12.08%	+19.46%	+9.14%	+686.52%

ACHC

ACHC fundamentals

ACHC Q4 2025 Earnings

Earnings Call

You can ask Aime

ACHC

ACHC fundamentals

ACHC Q4 2025 Earnings

Earnings Call

ACHC Earnings Call Summary for Q4/20259:00 AM on Feb 25, 2026

ACHC Earnings Call Summary for Q3/20259:00 AM on Nov 6, 2025

ACHC Earnings Call Summary for Q2/20259:00 AM on Aug 6, 2025

ACHC Earnings Call Summary for Q1/20258:30 AM on May 13, 2025

ACHC Earnings Call Summary for Q4/20249:00 AM on Feb 28, 2025

You can ask Aime